Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 34 clinical trials
9-ING-41 in Patients With Advanced Cancers

, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

metastatic malignancy
chemotherapy regimen
irinotecan
general anesthesia
carboplatin
  • 542 views
  • 01 Aug, 2021
  • 16 locations
Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer

was associated with overall survival (OS). Here, the investigators adopt the three active cytotoxic agents (Fluorouracil, Oxaliplatin, Irinotecan, FOLFOXIRI) as the neoadjuvant chemotherapy regimen to

adenocarcinoma of rectum
adenocarcinoma
xelox
chemoradiation therapy
irinotecan
  • 1 views
  • 22 Jan, 2021
Dose Individualization of Pemetrexed - IMPROVE-III

mesothelioma. Dosing of cytotoxic agents like pemetrexed requires balancing the dual risk of sub-therapy and toxicity. Administration of pemetrexed to patients with a creatinine clearance <45 ml/min is

impaired renal function
cytotoxic agents
folic acid
chemotherapy regimen
cancer chemotherapy
  • 0 views
  • 25 Sep, 2021
  • 5 locations
Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis

fibrogenic repair mediated by fibroblasts and myofibroblasts. One of the cytotoxic agents most widely used and better tolerated in the management of IPF is azathioprine. Based upon limited

pulmonary disease
corticosteroids
ct scan
prednisone
pneumonia
  • 31 views
  • 07 Nov, 2020
  • 1 location
Dose Individualization of Pemetrexed - IMPROVE-II

mesothelioma. Dosing of cytotoxic agents like pemetrexed requires balancing the dual risk of sub-therapy and toxicity. Administration of pemetrexed to patients with a creatinine clearance <45 ml/min is

impaired renal function
cytotoxic agents
folic acid
chemotherapy regimen
cancer chemotherapy
  • 14 views
  • 22 Sep, 2021
  • 5 locations
Dose Individualization of Pemetrexed - IMPROVE-I

mesothelioma. Dosing of cytotoxic agents like pemetrexed requires balancing the dual risk of sub-therapy and toxicity. Administration of pemetrexed to patients with a creatinine clearance <45 ml/min is

impaired renal function
cytotoxic agents
folic acid
chemotherapy regimen
cancer chemotherapy
  • 4 views
  • 23 Sep, 2021
  • 5 locations
Patients With ES-SCLC and ECOG PS=2 Receiving Atezolizumab-Carboplatin-Etoposide

SCLC patients develop brain metastases. New cytotoxic agents as well as targeted therapies have not been able to show any improvement of survival in this group of patients. Early phase

atezolizumab
neutrophil count
brain metastases
etoposide
carboplatin
  • 0 views
  • 07 May, 2021
  • 19 locations
Stereotaxic Body Irradiation of Oligometastase in Sarcoma (Stereosarc)

immunomodulatory agents appear to be synergistic and show favorable tolerance profiles. Immunomodulatory agents have a more favorable toxicity profile than cytotoxic agents with about 65% overall acute toxicities

leiomyosarcoma
soft tissue sarcoma
neutrophil count
cancer chemotherapy
tumor cells
  • 0 views
  • 09 Jul, 2021
  • 11 locations
Totally Neoadjuvant FOLFOXIRI + Short-course Radiation + XELOX in Patients With Locally Advanced Rectal Cancer

To evaluate the efficacy and safety of totally neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) followed by short-course radiation therapy and XELOX chemotherapy in the patients with locally advanced rectal cancer.

adenocarcinoma of rectum
platelet count
adenocarcinoma
neutrophil count
xelox
  • 0 views
  • 27 Apr, 2021
  • 1 location
The p53 Breast Cancer Trial

This is a multicenter, open labeled, phase 2 clinical trial, where patients are stratified to one of two treatment groups based on upfront TP53 mutation status; i.e. TP53 mutated vs. TP53 wt disease, and treated with dose-dense cyclphosphamide. Furthermore, patients included are stratified based on tumor stage; i.e. locally advanced …

  • 20 views
  • 15 Jun, 2021
  • 5 locations